




,

,

,

, and

or a pharmaceutically acceptable salt, solvate, N-oxide, or prodrug thereof.

61. A pharmaceutical composition comprising a compound of any of claims 1-60, or a pharmaceutically acceptable salt, solvate, N-oxide, or prodrug thereof; and a pharmaceutically acceptable excipient, binder or carrier.

62. ~~A method for treating an autoimmune disease comprising administering to a subject in need thereof~~ Use of a composition containing a therapeutically effective amount of a compound of any of claims 1-60 or the composition of claim 61, in the preparation of a medicament for treating an autoimmune disease.

63. ~~A method for treating a heteroimmune condition or disease comprising administering to a subject in need thereof~~ Use of a composition containing a therapeutically effective amount of a compound of any of claims 1-60 or the composition of claim 61, in the preparation of a medicament for treating a heteroimmune condition or disease .

64. ~~A method for treating an inflammatory disease comprising administering to a subject in need thereof~~Use of a composition containing a therapeutically effective amount of a compound of any of claims 1-60 or the composition of claim 61, in the preparation of a medicament for treating an inflammatory disease.

65. ~~A method for treating a cancer comprising comprising administering to a subject in need thereof~~ Use of a composition containing a therapeutically effective amount of a compound of any of claims 1-60 or the composition of claim 61, in the preparation of a medicament for treating a cancer .

66. The ~~method~~ use of claim 65, wherein the cancer is a B-cell proliferative disorder.

67. The ~~method~~ use of claim 66, wherein the B-cell proliferative disorder is chronic lymphocytic lymphoma, diffuse large B cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia.